GSK PLC (GLAXF) filings document foreign-issuer disclosures for a global biopharma company registered in England and Wales. The record centers on Form 6-K current reports furnished under the Exchange Act, including announcements on product collaborations, capital-return programs, annual general meeting voting results, remuneration matters, board elections, and transaction notifications involving American Depositary Shares.
The filings also describe GSK's securities framework, including ordinary shares and ADS instruments, share repurchases and treasury-share treatment, PDMR transaction reporting, and governance resolutions connected with annual reporting and shareholder approvals. Product-related reports identify bepirovirsen in chronic hepatitis B and outline regulatory, quality, pharmacovigilance, commercial access, and global medical-strategy responsibilities associated with collaboration arrangements.
GSK plc reported that two senior executives received notional share awards under its Deferred Investment Award programme. On 12 February 2026, President Europe Lynn Baxter and Chief Patient Officer Mondher Mahjoubi were each granted awards over 3,020 notional Ordinary Shares at a reference price of £21.41 per share.
The awards are designed to reward outstanding performance during 2025 and align management with shareholders. They vest on 12 February 2029, provided the recipients remain with the company and are not terminated for cause. No dividends accrue during the vesting period and, on vesting, the awards will be settled in cash rather than actual shares. Executive Directors are not eligible to receive awards under this programme.
GSK plc filed a Form 13F reporting holdings. The filing lists 15 reported positions with a combined market value of $799,022,938. The report is signed by Victoria Whyte as Authorised Signatory and dated 02-12-2026.
GSK plc reported several routine share dealings by senior leaders and a person closely associated with a leader. Multiple executives, including the President, Europe and the Chief Financial Officer, each acquired 10 or 12 ordinary shares at £21.7918 under the Company’s Share Reward Plan on 2026-02-10 via the London Stock Exchange.
The filing also notes that the Chief People Officer sold 10,000 American Depositary Shares at $59.1802 per ADS on 2026-02-09 on the New York Stock Exchange. All transactions are classified as initial notifications and involve GSK ordinary shares or ADS representing the company.
GSK plc reports that deferred bonus awards granted in 2023 under its 2017 Deferred Annual Bonus Plan have vested after a three-year restricted period ending 8 February 2026. The awards covered senior executives, including the Chief Executive Officer and other key leaders.
UK-based participants received nil-cost options over Ordinary Shares, while US participants received American Depositary Shares. On 9 February 2026, awards vested and options were exercised, for example Luke Miels exercised 60,334 Ordinary Shares. Portions of the resulting Ordinary Shares and ADS were then sold on the London and New York stock exchanges solely to meet tax liabilities.
GSK plc filed a Form 6-K detailing cash settlements of deferred incentive awards for three senior executives under the GlaxoSmithKline Deferred Investment Award Programme. The final 25% of awards granted on 10 February 2021 vested on 10 February 2026, based on GSK ordinary shares.
Chief Executive Officer Luke Miels and CEO, ViiV Healthcare and President, Global Health, GSK Deborah Waterhouse will each receive a cash payment of £541,555.40, reflecting 24,979.493 notional ordinary shares at £21.68. Regis Simard, President, Global Supply Chain, will receive £270,777.70 in cash in respect of 12,489.746 notional ordinary shares, also priced at £21.68, in each case before tax withholding.
GSK plc reports that several senior leaders and a person closely associated with a leader had conditional awards from the 2023 GSK Share Value Plan vest on 9 February 2026. These covered Ordinary Shares and American Depositary Shares granted for continued employment.
On the same date, portions of these vested shares were sold on the London Stock Exchange at £21.9082 per Ordinary Share and on the New York Stock Exchange at $59.0729 per ADS to meet related tax liabilities. Individual vestings and sales ranged from around 10,050 to 23,120 Ordinary Shares and 10,658 ADS, reflecting routine share plan settlements for compensation rather than new capital raising.
GSK plc reports that China's Center for Drug Evaluation has accepted its application for Arexvy, an RSV vaccine, to prevent lower respiratory tract disease in adults aged 60 and older. A regulatory decision is expected in 2027.
If approved, Arexvy would be the first vaccine in China for RSV-related lower respiratory disease in this older population, where RSV is estimated to affect more than six million adults and cause over 350,000 hospitalisations each year. The submission is supported by a robust Phase III data package in Chinese adults that met all primary immunogenicity endpoints and showed an acceptable safety profile.
The vaccine, already approved for older adults in many countries, uses a recombinant RSVPreF3 antigen with GSK's AS01E adjuvant to boost immune response, though protection is not guaranteed in all recipients.
GSK plc filed a report detailing an internal transaction by non-executive director Dr Hal Barron. On 2026-02-05, Dr Barron recorded a disposal of notional American Depositary Shares in his GSK Executive Supplemental Savings Plan account, involving 67,601.825 ADSs at $59.1700 per ADS.
GSK plc reported an insider share purchase by its Non-Executive Chair, Sir Jonathan Symonds. He bought 2,500 ordinary shares of 31¼ pence each at a price of £21.1400 per share on 5 February 2026 on the London Stock Exchange. This Form 6-K records the required PDMR (person discharging managerial responsibilities) transaction notification for the company’s ordinary shares.
GSK plc reports that the European Commission has approved Nucala (mepolizumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterised by raised blood eosinophils despite inhaled triple therapy (ICS, LABA, LAMA).
The approval is based on the phase III MATINEE trial, where mepolizumab reduced the annualised rate of moderate or severe COPD exacerbations versus placebo plus standard of care, with a rate ratio of 0.79 and annualised exacerbation rates of 0.80 versus 1.01. MATINEE also showed a reduction in exacerbations requiring emergency department visits and/or hospitalisation, with a rate ratio of 0.65 and annualised rates of 0.13 versus 0.20.
Nucala is described as the first and only monthly biologic in the EU evaluated in a wide COPD population with an eosinophilic phenotype, and is now approved in Europe across five indications driven by type 2 inflammation, including COPD, severe asthma, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome.